Recent investigations have centered on the intersection of GLP-1|GIP|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GLP activators are increasingly employed for managing type 2 diabetes, https://tirzepatide380101.fitnell.com/82916996/novel-gcgr-stimulators-and-dopaminergic-adjustment-a-comparative-overview